<DOC>
	<DOCNO>NCT01125514</DOCNO>
	<brief_summary>This study assess interaction single multiple dos aliskiren ( 150 mg 300 mg ) furosemide ( 60 mg ) patient heart failure .</brief_summary>
	<brief_title>A Study Investigate Pharmacodynamic Pharmacokinetic Interaction Between Aliskiren Furosemide Patients With Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Furosemide</mesh_term>
	<criteria>Systolic diastolic heart failure , diagnose either NYHA functional class II III least 3 month prior screen stable medication least 12 week . Patients must meet either criterion screening : Documented leave ventricular ejection fraction ( LVEF ) great 20 % low 40 % OR Patients document LVEF great 40 % history NTproBNP &gt; 400pg/mL ( BNP &gt; 100pg/mL ) within 12 month screen . Treatment Angiotensin Receptor Blockers ( ARBs ) , aldosterone receptor antagonist diuretic ( furosemide ) within 3 week first dose study . Beta blocker permit provide dose stable least 3 week first dose remains throughout study . Hypertrophic cardiomyopathy ( HCMP ) . If subject currently treat furosemide , dose must stable least 3 week first dose dose must exceed 60 mg daily Stable heart failure require treatment ACE inhibitor ARB Current acute decompensated heart failure . Mean sit systolic blood pressure ≥160 mmHg and/or mean sit diastolic blood pressure ≥ 100mmHg and/or secondary form hypertension . Persistent sit systolic blood pressure &lt; 90 mmHg . History angioedema . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Heart failure ,</keyword>
	<keyword>aliskiren ,</keyword>
	<keyword>furosemide ,</keyword>
	<keyword>diuretic efficacy ,</keyword>
	<keyword>interaction</keyword>
</DOC>